Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

HER2-resisting antibody-medicine conjugate and applications thereof

A technology of drug conjugates and conjugates, applied in the direction of antibodies, drug combinations, anti-tumor drugs, etc., can solve problems such as difficult separation of antibody-drug conjugate mixtures

Active Publication Date: 2017-08-11
HANGZHOU ADCORIS BIOPHARMA CO LTD
View PDF7 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Analytical and preparative methods can make it difficult to separate and characterize antibody-drug conjugate mixtures resulting from the heterogeneity of the conjugation reactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • HER2-resisting antibody-medicine conjugate and applications thereof
  • HER2-resisting antibody-medicine conjugate and applications thereof
  • HER2-resisting antibody-medicine conjugate and applications thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0223] The coupling modes for preparing the antibody-drug conjugate of the present invention include two coupling modes, K-Lock and C-Lock. In the K-Lock coupling method, the drug molecule is coupled to the lysine (K) residue in the antibody sequence, and in the C-Lock coupling method, the drug molecule is coupled to the cysteine ​​residue in the antibody sequence (C) The conjugation method of the antibody-drug conjugate of the present invention is outlined below.

[0224] K-Lock method: Antibodies can be directly linked to L1-D in a mild solution system. For example, use 6-10 times excess L1-D to react with antibody for 3-16 hours at room temperature, and ultra-filter to remove excess small molecule L1-D. The antibody-drug conjugate was loaded onto a hydrophobic chromatography column (HIC), and purified to obtain an anti-HER2 antibody-drug conjugate with a coupling number of 2.

[0225] C-Lock method: After the antibody is reduced by TCEP, it is directly linked to L2-D in a...

Embodiment 1

[0243] The synthesis of embodiment 1 compound 7

[0244]

[0245] Synthesis of compound 3:

[0246] Compound 2 (261 mg, 0.52 mmol) was dissolved in 6 mL of DMF, and HATU (217 mg, 0.57 mmol), DIEA (362 μL, 2.08 mmol), and amino compound 1 (213 mg, 0.52 mmol) were added. Stir for 30 minutes, then add 400 μL of piperidine, and continue stirring for 10 minutes. The reaction solution was concentrated and directly purified by HPLC to obtain compound 3 (171 mg, 60%). MS m / z 548.3 (M+H).

[0247] Compound 5:

[0248] Compound 4 (37 mg, 0.15 mmol) was dissolved in 4 mL of DMF, and HATU (59 mg, 0.15 mmol), DIEA (108 μL, 0.6 mmol), and amino compound 3 (102 mg, 0.15 mmol) were added. The reaction solution was stirred for 30 minutes, evaporated to dryness under reduced pressure, then dissolved in 2 mL of dichloromethane, added with 1 mL of TFA and stirred for 10 minutes. The reaction solution was evaporated to dryness under reduced pressure and purified by HPLC to obtain compound ...

Embodiment 2

[0251] The synthesis of embodiment 2 compound 11

[0252]

[0253] Compound 2 (130 mg, 0.26 mmol) was dissolved in 3 mL of DMF, HATU (110 mg, 0.29 mmol), DIEA (175 μL, 1 mmol), and amino compound 1 (110 mg, 0.27 mmol) were added. The reaction solution continued to stir for 30 minutes, and was rotary evaporated to dryness. The residue was dissolved in TFA / dichloromethane (1 / 4, v / v, 5 mL) and stirred for 30 minutes. The reaction solution was evaporated to dryness under reduced pressure and purified by HPLC to obtain compound 8 (108 mg, 65%). MS m / z 670.5 (M+H).

[0254] Compound 6 (85 mg, 0.12 mmol) was dissolved in 2 mL of DMF, HATU (48 mg, 0.12 mmol), DIEA (83 μL, 0.48 mmol), and amino compound 8 (94 mg, 0.12 mmol) were added. The reaction solution was stirred for 30 minutes, then piperidine (0.2 mL) was added and stirred for 30 minutes. The reaction solution was concentrated and purified by HPLC to obtain compound 9 (87 mg, 63%). MS m / z 1028.7 (M+H).

[0255]To a solu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an HER2-resisting antibody-medicine conjugate and applications of the HER2-resisting antibody-medicine conjugate. Specifically, the invention provides the HER2-resisting antibody-medicine conjugate. The experimental result proves that the antibody-medicine conjugate has the obvious anti-tumor effect. The invention further discloses the pharmacy applications of the HER2-resisting antibody-medicine conjugate, and the effects of the HER2-resisting antibody-medicine conjugate in inhibiting or preventing tumor.

Description

technical field [0001] The invention belongs to the field of biomedicine, in particular, the invention relates to an anti-HER2 antibody-drug conjugate. Background technique [0002] The HER family of receptor tyrosine kinases are important mediators of cell growth, differentiation and survival. This family of receptors includes four distinct members: HER1 (EGFR or ErbB1), HER2 (ErbB2 or p185neu), HER3 (ErbB3) and HER4 (ErbB4 or tyro2). [0003] In addition to HER2 itself, specific ligand binding to the ectodomain of EGFR, HER3, and HER4 all leads to the formation of complexes of homodimeric or heterodimeric kinase activity, in which HER2 is the preferred part. Although HER2 cannot directly interact with HER-activating ligands, it is well established that its kinase is able to signal HER2-containing heterodimers and increase ligand binding affinity to EGFR or HER3. The formation of HER2 dimers triggers a series of processes in the cell that culminate in increased cell motil...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/68A61K38/08A61P35/00
CPCA61K38/08A61K38/07C07K16/32A61K2039/505C07K2317/73C07K2317/92A61K47/6803A61K47/6855A61K47/6857A61K47/6863A61K47/6869A61K47/6849A61P35/00C07D419/12C07D419/10A61K31/427C07D207/08C07D401/12A61K47/6811
Inventor 苗振伟朱同阿里舍尔B·卡萨诺夫陈刚李朝辉曹小冬
Owner HANGZHOU ADCORIS BIOPHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com